For example, the recombinant human tripeptidyl peptidase 1 enzyme (cerliponase alfa) has been delivered as the first approved therapy via ICV infusion to treat patients with neuronal ceroid lipofuscinosis type 2 (CLN2) [24]. The gene discussed is TPP1; the disease is neuronal ceroid lipofuscinosis.